Pharmaceutical Companies

Under the agreement, Roche’s Genentech subsidiary will oversee development, regulatory activities, manufacturing and commercialisation across all indications.

IntraBio will become a wholly owned subsidiary of Shionogi Inc., the Japanese group’s US-based subsidiary in New Jersey.

The Bristol site’s focus on GMP small molecules adds to this portfolio, extending the company’s capacity to supply materials used in the development and production of advanced therapies.

The planned campus at the New Albany International Business Park will use a flexible, modular design combining drug substance and drug product manufacturing with digital and automation technologies.

The NMPA approved VELSIPITY in February 2026 for adults with moderately to severely active ulcerative colitis (UC) who had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.

It is now integrating those businesses under Asahi Kasei Therapeutics, the name of its existing Japanese pharmaceutical unit.

The deal gives Kyowa Kirin access to Knight’s pan-American commercial infrastructure while allowing Knight to add a targeted oncology therapy to its portfolio.

Sanofi will pay Regeneron US$1 billion upfront, with development, regulatory, and commercial milestones potentially adding another US$ 7 billion.

The Mainz-based biopharmaceutical company said the closures will affect about 1,800 employees at sites in Tübingen, Marburg and Idar-Oberstein.

Profluent will conduct the computational design work using its Profluent Protein Atlas, a dataset containing more than 115 billion unique protein sequences.